The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
Abstract
BACKGROUND: Duchenne's muscular dystrophy is associated with severe, progressive muscle weakness and typically leads to death between the ages of 20 and 35 years. By inducing specific exon skipping during messenger RNA (mRNA) splicing, antisense compounds were recently shown to correct the open reading frame of the DMD gene and thus to restore dystrophin expression in vitro and in animal models in vivo. We explored the safety, adverse-event profile, and local dystrophin-restoring effect of a single, intramuscular dose of an antisense oligonucleotide, PRO051, in patients with this disease. METHODS: Four patients, who were selected on the basis of their mutational status, muscle condition, and positive exon-skipping response to PRO051 in vitro, received a dose of 0.8 mg of PRO051 injected into the tibialis anterior muscle. A biopsy was performed 28 days later. Safety measures, composition of mRNA, and dystrophin expression were assessed. RESULTS: PRO051 injection was not associated with clinically apparent adverse events. Each patient showed specific skipping of exon 51 and sarcolemmal dystrophin in 64 to 97% of myofibers. The amount of dystrophin in total protein extracts ranged from 3 to 12% of that found in the control specimen and from 17 to 35% of that of the control specimen in the quantitative ratio of dystrophin to laminin alpha2. CONCLUSIONS: Intramuscular injection of antisense oligonucleotide PRO051 induced dystrophin synthesis in four patients with Duchenne's muscular dystrophy who had suitable mutations, suggesting that further studies might be feasible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H., & Kunkel, L. M. (1988) · Genomics · doi:10.1016/0888-7543(88)90113-9 · Cited by 1,210
Dystrophin and mutations: one gene, several proteins, multiple phenotypes
Muntoni, F., Torelli, S., & Ferlini, A. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00585-4 · Cited by 1,124
Eagle, M., Baudouin, S. V., Chandler, C., Giddings, D. R., Bullock, R., & Bushby, K. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00140-2 · Cited by 1,009
Koenig, M., Beggs, A. H., Moyer, M., Scherpf, S., Heindrich, K., Bettecken, T., Meng, G., Müller, C. R., Lindlöf, M., Kääriäinen, H. A., et al. (1989) · Europe PMC (PubMed Central) · Cited by 961
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805263182104 · Cited by 927
Aartsma‐Rus, A., Van Deutekom, J. C. T., Fokkema, I. F., Van Ommen, G. B., & Den Dunnen, J. T. (2006) · Muscle & Nerve · doi:10.1002/mus.20586 · Cited by 739
Self-citationVery mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623
Glucocorticoid corticosteroids for Duchenne muscular dystrophy
Manzur, A., Kuntzer, T., Pike, M., & Swan, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub2 · Cited by 539
Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S. D., Partridge, T. A., & Lu, Q. L. (2006) · Nature Medicine · doi:10.1038/nm1345 · Cited by 494
Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy
Simonds, A. K., Muntoni, F., Heather, S., & Fielding, S. (1998) · Thorax · doi:10.1136/thx.53.11.949 · Cited by 414
Duchenne muscular dystrophy: Pathogenetic aspects and genetic prevention
Moser, H. (1984) · Human Genetics · doi:10.1007/bf00275183 · Cited by 413
Lu, Q. L., Rabinowitz, A., Chen, Y. C., Yokota, T., Yin, H., Alter, J., Jadoon, A., Bou-Gharios, G., & Partridge, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406700102 · Cited by 402
Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells
van Deutekom, J. C. T. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.15.1547 · Cited by 293
Self-citationTherapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients
Aartsma-Rus, A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg100 · Cited by 253
Self-citationMcClorey, G., Moulton, H. M., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302800 · Cited by 207
Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense
Aartsma-Rus, A., Janson, A. A. M., Kaman, W. E., Bremmer-Bout, M., van Ommen, G.-J. B., den Dunnen, J. T., & van Deutekom, J. C. T. (2004) · The American Journal of Human Genetics · doi:10.1086/381039 · Cited by 200
Self-citationExploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of Disease
Havenga, M. J. E., Lemckert, A. A. C., Ophorst, O. J. A. E., van Meijer, M., Germeraad, W. T. V., Grimbergen, J., van den Doel, M. A., Vogels, R., van Deutekom, J., Janson, A. A. M., et al. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4612-4620.2002 · Cited by 192
Self-citationTargeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy
Aartsma-Rus, A., Bremmer-Bout, M., Janson, A. A. M., den Dunnen, J. T., van Ommen, G.-J. B., & van Deutekom, J. C. T. (2002) · Neuromuscular Disorders · doi:10.1016/s0960-8966(02)00086-x · Cited by 175
Self-citationMercuri, E., Bushby, K., Ricci, E., Birchall, D., Pane, M., Kinali, M., Allsop, J., Nigro, V., Sáenz, A., Nascimbeni, A., et al. (2005) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.10.008 · Cited by 163
Yuan, H., Takeuchi, E., Taylor, G. A., McLaughlin, M. M., Brown, D., & Salant, D. J. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v134946 · Cited by 118
Aartsma-Rus, A. M., de Winter, C. L., Janson, A. A. M., Kaman, W. E., van Ommen, G. B., den Dunnen, J. T., & van Deutekom, J. C. T. (2005) · Oligonucleotides · doi:10.1089/oli.2005.15.284 · Cited by 111
Self-citationPercutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool.
Dorph, C., Nennesmo, I., & Lundberg, I. E. (2001) · PubMed · Cited by 86
Duchenne muscular dystrophy, 2nd edn.
Dubowitz, V. (1993) · Neuromuscular Disorders · doi:10.1016/0960-8966(93)90016-d · Cited by 80
Takeshima, Y., Wada, H., Yagi, M., et al. (2001) · Brain and Development · doi:10.1016/s0387-7604(01)00326-6 · Cited by 80
Ultrastructural localization of adhalin, α‐dystroglycan and merosin in normal and dystrophic muscle
Cullen, M. J., Walsh, J., Roberds, S. L., et al. (1996) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1996.tb00843.x · Cited by 25
Cited by
Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., Kaul, A., Kinnett, K., McDonald, C., Pandya, S., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70271-6 · Cited by 2,053
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046
Therapeutic targeting of microRNAs: current status and future challenges
Li, Z., & Rana, T. M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4359 · Cited by 1,033
Non-coding RNAs as drug targets
Matsui, M., & Corey, D. R. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.117 · Cited by 1,032
Metadata
- Authors
- van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., de Kimpe, S. J., Ekhart, P. F., Venneker, E. H., Platenburg, G. J., Verschuuren, J. J., & van Ommen, G.-J. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-12-27
- Volume
- 357
- Issue
- 26
- Pages
- 2677-2686
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2010757394
- Cited by
- 781
- References
- 25
- FWCI
- 27.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.